According to Fintel’s reports on May 26, 2023, HC Wainwright & Co. reiterated its coverage of Gracell Biotechnologies Inc – ADR (NASDAQ:GRCL) with a Buy recommendation.
As of May 11, 2023, the average one-year price target for Gracell Biotechnologies Inc – ADR is 12.82, ranging from a low of 7.07 to a high of $21.00. This average price target indicates that there is an increase of 357.96% from its latest reported closing price of 2.80.
If you are interested, check out the leaderboard of companies with the largest price target upside.
The projected annual revenue for Gracell Biotechnologies Inc – ADR is 0MM, with an annual non-GAAP EPS of -0.59.
The number of funds or institutions reporting positions in Gracell Biotechnologies Inc – ADR increased by 1 or 2.00% in the last quarter, with an average portfolio weight of all funds dedicated to GRCL decreasing by 0.82%. The total shares owned by institutions increased by 44.19% to 31,664K shares over the last three months.
The major shareholders of the company include Temasek Holdings, Orbimed Advisors, Great Point Partners, Sphera Funds Management, and Vivo Capital.
Gracell Biotechnologies Inc is a biotechnology company that focuses on developing and commercializing cell therapies for various cancer indications.
Originally published on Fintel.
The statements and opinions expressed here are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
